©2025 Stanford Medicine
Aromatherapy Inhaler Use for HSCT Distress
Recruiting
I'm InterestedTrial ID: NCT05302583
Purpose
This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.
Official Title
Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress
Stanford Investigator(s)
Andrew Rezvani, M.D.
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:
* Autologous and Allogeneic patients admitted to E1 for planned HSCT
* Patients with hematologic malignancies requiring HSCT
* No allergies to lavender or peppermint essential oils
* Must have received chemotherapy during preparative regimen (single or multi-agent regimen)
* Adult patient over 18 years of age
* Able to speak, read, and comprehend English
* Willing and capable of providing informed consent
Exclusion Criteria:
* Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion
* Patients receiving a transplant for a germ cell tumor diagnosis
* Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)
* Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4
* History of scleroderma
* History of atrial fibrillation
* Known history of G6PD deficiency
* Allergic to lavender or peppermint essential oils
* Pediatric patient 18 years of age or less
* Unable to speak, read, and comprehend English
* Unwilling or incapable of providing informed consent
Intervention(s):
other: Aromatherapy Inhaler
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Aubrey L Florom-smith, PhD, RN
650-285-9512